Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.10.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Research and development    
Compensation and benefits $ 557,391 $ 1,500,864
Consultants and outside costs 46,705 130,361
Material manufacturing costs 72,932 426,089
Facilities and other costs 249,698 502,657
Total research and development 929,909 4,310,637
General and administrative    
Compensation and benefits 1,249,696 1,795,427
Professional fees 121,923 223,594
Investor relations 44,013 59,871
General and administrative 239,340 327,600
Loss (Gain) on sale of fixed assets (22,852) 0
Total General and Administrative 1,632,120 2,406,492
Total operating expenses 2,562,029 6,717,129
Loss from operations (2,562,029) (6,717,129)
Other income (expense)    
Interest income 28 337
Rent income 89,466 31,838
Interest expense (911,602) 0
Derivative gains 18,904 342
Total other income (803,204) 32,517
Net loss (3,365,233) (6,684,612)
Net loss attributable to common stock $ (3,365,233) $ (6,684,612)
Net loss per common share - basic and diluted $ (0.05) $ (0.13)
Weighted average number of common shares outstanding - basic and diluted 62,166,309 52,887,981
Clinical trial costs    
Research and development    
Cost of Goods and Services Sold $ 3,184 $ 979,766
License costs    
Research and development    
Cost of Goods and Services Sold $ 0 $ 770,900